Taylors ready to sate China thirst for its top-shelf wines
One of Australia’s largest family-owned wine groups has ambitious expectations for its return to China and anticipates strong demand for its most expensive products.
Matt Bell
Latest
Cautious start for ASX as investors await CPI data
The local bourse is set for a low-key start to the week, as investors wait on inflation data that will play a major part in when the RBA decides to move on interest rates.
Administrators raking in millions as firms fail
Major accounting firms are collecting millions of dollars in remuneration as a growing number of large businesses collapse amid a deterioration in Australia’s economy.
‘We need migrants and new rules to boost housing’
Australian property industry experts have told a national conference that Australia will damage its international standing if it makes it harder for foreigners to invest here.
More housing help needed for young buyers: Mirvac
The developer says the government needs to look at reducing APRA mortgage buffers and offering loans to make housing accessible.
Administration the go-to rescue plan for growing number of execs
The number of Australian executives putting their companies into voluntary administration in a bid to turn their flagging fortunes around is growing, ASIC figures show.
Audiovisual specialist Audinate shelves its target
Audiovisual company Audinate has told investors it’s had weaker-than-expected demand from customers and that’s led to revised financial targets.
Insolvencies: one area of the economy going gangbusters
Businesses are going bust at a faster rate than at any other time in the nation’s history, as the combination of rising costs and an economic slowdown push small firms over the edge.
ASX poised for more IPOs as conditions turn
Market watchers say interest rate cuts and improving economic conditions will make IPOs more attractive for companies, as one Aussie wool group prepares to list to fuel ambitious growth plans.
Health darling launches fresh bid to list on Nasdaq
Telix Pharmaceuticals won’t raise capital as it looks to capture the attention of more global investors under fresh plans to list on the Nasdaq.
Original URL: https://www.theaustralian.com.au/author/matt-bell/page/8